Stoke Therapeutics (NASDAQ:STOK) Price Target Increased to $21.00 by Analysts at Canaccord Genuity Group

Stoke Therapeutics (NASDAQ:STOK) had its target price hoisted by analysts at Canaccord Genuity Group from $18.00 to $21.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 48.20% from the company’s previous close.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Stoke Therapeutics in a report on Friday, February 16th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.63.

Stoke Therapeutics Stock Up 37.7 %

Shares of NASDAQ STOK opened at $14.17 on Tuesday. The stock has a market capitalization of $632.69 million, a P/E ratio of -5.98 and a beta of 0.68. The stock’s 50 day moving average price is $5.88 and its two-hundred day moving average price is $4.95. Stoke Therapeutics has a 52-week low of $3.35 and a 52-week high of $16.40.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the transaction, the chief executive officer now directly owns 69,350 shares of the company’s stock, valued at approximately $423,035. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the sale, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Edward M. Md Kaye sold 11,150 shares of the company’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the sale, the chief executive officer now directly owns 69,350 shares of the company’s stock, valued at approximately $423,035. The disclosure for this sale can be found here. Over the last three months, insiders have sold 37,615 shares of company stock worth $212,852. 12.30% of the stock is owned by insiders.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP lifted its holdings in shares of Stoke Therapeutics by 514.7% in the third quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock valued at $1,371,000 after buying an additional 291,443 shares during the period. Trexquant Investment LP grew its stake in shares of Stoke Therapeutics by 166.9% in the 3rd quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock worth $503,000 after purchasing an additional 79,785 shares during the last quarter. Principal Financial Group Inc. bought a new stake in shares of Stoke Therapeutics in the 2nd quarter worth approximately $121,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Stoke Therapeutics by 9.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock valued at $576,000 after purchasing an additional 12,478 shares during the last quarter. Finally, Corton Capital Inc. bought a new stake in Stoke Therapeutics during the third quarter worth approximately $58,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.